Orthofix Medical (NSDQ:OFIX) announced today that it won FDA approval for its STIM onTrack mobile app version 2.1 for use with its bone growth stimulators.
STIM onTrack is designed to work with Orthofix’s bone growth therapy devices as an accessory to help users adhere to prescriptions and improve clinical out comes. It is supposed to augment treatment with Orthofix’s CervicalStim, SpinalStim and PhysioStim bone growth stimulators.
The latest version (2.1) of the app, which was initially released in 2017, hosts patient-reported outcome measure (PROM) questionnaires to enable users to remotely share the status of their quality of life and well-being with their physician, according to a news release.
The app also offers daily treatment reminders and a device usage calendar to allow physicians to remotely view patient data to monitor their treatment. Lewisville, Texas-based Orthofix offers the app for free on iOS and Android device platforms.
“We are proud to be the first in the bone growth stimulation market to be able to deliver tools to support physician remote patient monitoring endeavors to aid in a joint vision of improving patient outcomes,” Orthofix global president Kevin Kenny said in the news release.
“We know that patients who take an active role in their follow-up care have an overall better recovery experience and outcomes,” added Yale University School of Medicine associate professor of orthopedics and rehabilitation Dr. Peter Whang. “The STIM onTrack mobile app version 2.1 is very beneficial for tracking adherence to their treatment plan, and the addition of the PROM questionnaire feature provides us with even more insights on how the patient is responding in their home setting, not just when they visit our office.”